Shibani Malhotra

Allergan Now Trades Cheaper Than Its Standalone Value

Endo's Selloff An 'Overreaction,' Nomura Says

Nomura Downgrades Valeant, Says It's Been 'Humbled'

Endo's Selloff An 'Overreaction,' Nomura Says

Nomura Downgrades Valeant, Says It's Been 'Humbled'

These Four Analysts Remain Bullish On Valeant

5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

These Four Analysts Remain Bullish On Valeant

5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

Actavis' Growth 'Underappreciated,' Sterne Agee Says

Sterne Agee Analyst: Court Win To Boost Net At Teva Pharmaceutical

Shibani Malhotra Recent News

UPDATE: Sterne Agee Upgrades Teva Pharmaceutical

Sterne Agee Says Salix Pharmaceuticals Accounting Concerns Are 'Overdone'

Sterne Agee Sees Entry Point In Endo International PLC Shares

Sterne Agee Still Has Confidence In Actavis plc

Sterne Agee Raises Actavis plc Estimates, Price Target

Sterne Agee Adjusts Estimates For Salix Pharmaceuticals

Sterne Agee Feels More Positive On Allergan Following Recent Call With CEO

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On FDA Panel Outcome

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ahead Of FDA Panel Vote

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On Upcoming Catalysts

UPDATE: Sterne Agee Reiterates On Actavis PLC On Good Market Position

Sterne Agee Believes Allergan Is In Stronger Position Than Originally Thought

Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries Ltd.

Sterne Agee Sees Good Things Ahead for Endo International PLC

Sterne Agee Expects Allergan to Resist Hostile Takeover by Valeant

Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage

Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing